Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Symbiomix Therapeutics
Age
12–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Are premenopausal adult females or post menarchal adolescent girls ≥12 years of age in good general health
Have a clinical diagnosis of bacterial vaginosis, defined as having all of the following criteria:
Off-white (milky or gray), thin, homogeneous vaginal discharge
Vaginal pH ≥ 4.7
Presence of Clue cells of ≥ 20% of the total epithelial cells on microscopic examination of the vaginal saline wet mount
A positive 10% KOH Whiff test
Have a Gram stain slide Nugent Score ≥ 4 at the Baseline Visit (Day 1)
You may not be if
Are pregnant, lactating, or planning to become pregnant during the study
Are menstruating or have vaginal bleeding at the Baseline Visit (Day 1)
Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex
Have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days prior to the Baseline Visit (Day 1)
Clareo Health | A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
